55-meridian invests APT

The not-for-profit healthcare organization Hackensack Meridian Health has invested in the phage biotech company Adaptive Phage Therapeutics (APT). According to APT's CEO, Greg Merril, "The high level of interest from strategic and financial investors in support of our expanding clinical pipeline validates the potential phage therapy holds for patients."